# Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

> **NCT07302841** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **DRUG:** Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β

## Key facts

- **NCT ID:** NCT07302841
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-06-20
- **Final completion:** 2028-12-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07302841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07302841, "Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07302841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*